Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

The Impact Of An Intermittent Energy Restricted Diet On Insulin Sensitivity In Men and Women With Central Obesity (Met-IER)

13. September 2019 aktualisiert von: King's College London

A Randomised Controlled Trial Assessing The Impact Of An Intermittent Energy Restricted Diet On Weight Loss, Insulin Sensitivity and Heart Rate Variability In Men and Women With Central Obesity

An intermittent energy restricted (IER) diet may modify cardio-metabolic disease risk factors compared to an energy-matched continuous energy restricted (CER) diet. A randomised controlled parallel design trial will determine the impact of a short-term IER diet (2 consecutive days of very low calorie diet (VLCD), 5 days moderate energy restriction each week for a 4 week period), compared to a CER diet, on insulin sensitivity in healthy (disease-free) subjects with central obesity.

Studienübersicht

Detaillierte Beschreibung

Prediabetes rates in England have showed a marked increase, more than tripling between 2003 and 2011. It is characterised by an impaired fasting glucose or impaired glucose tolerance that increases the risk of progression to type 2 diabetes (T2D). It has been estimated that approximately 90% of T2D is attributed to excess weight. Central obesity is a primary driver of increased cardiometabolic risk due to its lipotoxicity effects, promoting a proinflammatory state that facilitates insulin resistance and beta cell dysfunction. A high waist circumference measurement, indicative of central obesity, is associated with increased risk of cardiovascular diseases and T2D, and is a stronger predictor of T2D than BMI. BMI has limitations as an indicator of adiposity since it doesn't distinguish lean from fat mass, and does not indicate body fat distribution. Conventionally, continuous energy restriction (CER) diets have been used for weight loss, which consist of a constant daily energy deficit relative to total energy expenditure. The impact on weight loss and health of an intermittent energy restriction (IER) approach has only rarely been investigated (although the "5:2 diet" has been popularised in lifestyle books aimed at the general public). An IER diet consists of a predefined period of time severely restricting energy intake, alternated with a period of greater energy intake. This approach was shown to confer metabolic benefits in overweight and obese women at risk of breast cancer with baseline BMI of 2445 (Harvie et al., 2013; Harvie et al., 2011).

Rationale: An IER diet using meal replacements (VLCD foodpacks used as total dietary replacements for 2 consecutive days each week, and a food-based energy-restricted diet for the other 5 days of the week) may modify cardio-metabolic disease risk factors compared to an energy-matched CER diet.

Research question: In centrally obese subjects, assessed by a high waist circumference measurement, does adherence to an IER diet have enhanced cardio-metabolic benefits compared to a CER diet? Hypothesis: Increases in insulin sensitivity following a 4 week dietary intervention with an IER weight loss programme will be greater compared to a standard CER programme.

Objectives:

  1. A randomised controlled parallel design trial will determine the impact of a short-term IER diet compared to a CER diet on primary outcome variables (insulin sensitivity) in healthy subjects with a high waist circumference.
  2. To assess the impact of an IER diet on secondary outcome variables, including body composition, heart rate variability (HRV, a measure of cardiac autonomic function, including parasympathetic and sympathetic activity), blood pressure, vascular function, other markers of insulin resistance, inflammation/adipokines, plasma lipid profile, plasma norepinephrine, ketosis, the gut microbiome and cognitive function in healthy subjects with a high waist circumference.

Studientyp

Interventionell

Einschreibung (Tatsächlich)

42

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

    • England
      • London, England, Vereinigtes Königreich, SE1 9NH
        • Diabetes & Nutritional Sciences Division, King's College London, Franklin-Wilkins Buiding, 150 Stamford St.

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

35 Jahre bis 75 Jahre (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Ja

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • Aged >35-75 years
  • Waist circumference above cut-off for high risk of cardio-metabolic disease of >102 cm in men with a Europid, Black African and Caribbean, and other ethnic background and >88 cm in women with a Europid, Black African and Caribbean, and other ethnic background (WHO, 2008), and ≥90 cm in men and ≥80 cm in women with an Asian background (South Asian and East Asian) (Misra et al., 2009).

REFERENCES Misra A, Chowbey P, Makkar BM, Vikram NK, Wasir JS, Chadha D, et al. (2009). Consensus statement for diagnosis of obesity, abdominal obesity and the metabolic syndrome for Asian Indians and recommendations for physical activity, medical and surgical management. The Journal of the Association of Physicians of India 57: 163170.

WHO (2008). Waist circumference and waist-hip ratio: report of a WHO expert consultation. Geneva, 8-11 December 2008.

Exclusion Criteria:

  • Kidney or cardiovascular disease, cancer, diabetes, gastrointestinal or chronic liver disease;
  • previous bariatric surgery or other major surgery (e.g. organ transplantation);
  • unable to provide written informed consent;
  • have significant psychiatric disorder (e.g. schizophrenia, anxiety, panic disorder, attention deficit disorder, post-traumatic stress disorder, obsessive compulsive disorder) or uncontrolled depression;
  • participated in a weight management drug trial in the previous 3 months;
  • have binge eating behaviour;
  • have uncontrolled epilepsy;
  • alcohol or substance abuse;
  • currently pregnant, lactating, or planning pregnancy within the study period;
  • are using medication clinically deemed to affect metabolic rate and weight (e.g. beta blockers, corticosteroids, diuretics, etc);
  • lactose intolerant.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Verhütung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Intermittent Energy Restriction
Weight loss intervention: Intermittent Energy Restriction
Dietary advice to follow 5:2 diet supported by physical activity advice and motivational group support sessions
Aktiver Komparator: Continuous Energy Restriction
Weight loss intervention: Continuous Energy Restriction
Dietary advice to follow daily energy restricted diet supported by physical activity advice and motivational group support sessions

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Revised QUICKI (RQUICKI)
Zeitfenster: Baseline
Marker of insulin sensitivity
Baseline
RQUICKI
Zeitfenster: day 29
Marker of insulin sensitivity
day 29
RQUICKI
Zeitfenster: day 31
Marker of insulin sensitivity
day 31

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Körpergewicht
Zeitfenster: Grundlinie
Grundlinie
Taillenumfang
Zeitfenster: Grundlinie
Grundlinie
Hüftumfang
Zeitfenster: Grundlinie
Grundlinie
Plasmaglukosekonzentration
Zeitfenster: Grundlinie
Fasten
Grundlinie
Plasma-Adiponectin-Konzentration
Zeitfenster: Grundlinie
Fasten
Grundlinie
Plasma-Leptin-Konzentration
Zeitfenster: Grundlinie
Fasten
Grundlinie
Gesamtcholesterinkonzentration im Plasma
Zeitfenster: Grundlinie
Fasten
Grundlinie
Plasma-Cholesterinkonzentration von Low Density Lipoprotein (LDL).
Zeitfenster: Grundlinie
Fasten
Grundlinie
Plasmakonzentration von High Density Lipoprotein (HDL).
Zeitfenster: Grundlinie
Fasten
Grundlinie
Plasmatriglyceridkonzentration
Zeitfenster: Grundlinie
Fasten
Grundlinie
Plasma-Gesamtcholesterin:HDL-Cholesterin-Verhältnis
Zeitfenster: Grundlinie
Fasten
Grundlinie
Body-Mass-Index (BMI)
Zeitfenster: Grundlinie
Grundlinie
Plasma glucose concentration
Zeitfenster: day 29
Fasting
day 29
Plasma glucose concentration
Zeitfenster: day 31
Fasting
day 31
Plasma insulin concentration
Zeitfenster: Baseline
Fasting
Baseline
Plasma insulin concentration
Zeitfenster: day 29
Fasting
day 29
Plasma insulin concentration
Zeitfenster: day 31
Fasting
day 31
Plasma non-esterified fatty acid concentration
Zeitfenster: Baseline
Fasting
Baseline
Plasma non-esterified fatty acid concentration
Zeitfenster: day 29
Fasting
day 29
Plasma non-esterified fatty acid concentration
Zeitfenster: day 31
Fasting
day 31
Plasma total cholesterol concentration
Zeitfenster: day 29
Fasting
day 29
Plasma total cholesterol concentration
Zeitfenster: day 31
Fasting
day 31
Plasma LDL cholesterol concentration
Zeitfenster: day 29
Fasting
day 29
Plasma LDL cholesterol concentration
Zeitfenster: day 31
Fasting
day 31
Plasma HDL cholesterol concentration
Zeitfenster: day 29
Fasting
day 29
Plasma HDL cholesterol concentration
Zeitfenster: day 31
Fasting
day 31
Plasma triglyceride concentration
Zeitfenster: day 29
Fasting
day 29
Plasma triglyceride concentration
Zeitfenster: day 31
Fasting
day 31
Plasma total cholesterol:HDL cholesterol ratio
Zeitfenster: day 29
Fasting
day 29
Plasma total cholesterol:HDL cholesterol ratio
Zeitfenster: day 31
Fasting
day 31
Homeostasis model assessment estimated insulin resistance (HOMA-IR)
Zeitfenster: Baseline
Fasting (calculated from insulin and glucose)
Baseline
Homeostasis model assessment estimated insulin resistance (HOMA-IR)
Zeitfenster: day 29
Fasting (calculated from insulin and glucose)
day 29
Homeostasis model assessment estimated insulin resistance (HOMA-IR)
Zeitfenster: day 31
Fasting (calculated from insulin and glucose)
day 31
Plasma adiponectin concentration
Zeitfenster: day 29
Fasting
day 29
Plasma adiponectin concentration
Zeitfenster: day 31
Fasting
day 31
Plasma leptin concentration
Zeitfenster: day 29
Fasting
day 29
Plasma leptin concentration
Zeitfenster: day 31
Fasting
day 31
Plasma interleukin-6 concentration
Zeitfenster: Baseline
Fasting
Baseline
Plasma interleukin-6 concentration
Zeitfenster: day 29
Fasting
day 29
Plasma interleukin-6 concentration
Zeitfenster: day 31
Fasting
day 31
Plasma beta-hydroxybutyrate concentration
Zeitfenster: Baseline
Fasting
Baseline
Plasma beta-hydroxybutyrate concentration
Zeitfenster: day 29
Fasting
day 29
Plasma beta-hydroxybutyrate concentration
Zeitfenster: day 31
Fasting
day 31
Plasma norepinephrine concentration
Zeitfenster: Baseline
Fasting
Baseline
Plasma norepinephrine concentration
Zeitfenster: day 29
Fasting
day 29
Plasma norepinephrine concentration
Zeitfenster: day 31
Fasting
day 31
Plasma soluble alpha-klotho concentration
Zeitfenster: Baseline
Fasting
Baseline
Plasma soluble alpha-klotho concentration
Zeitfenster: day 29
Fasting
day 29
Plasma soluble alpha-klotho concentration
Zeitfenster: day 31
Fasting
day 31
Body weight
Zeitfenster: day 29
day 29
Body weight
Zeitfenster: day 31
day 31
BMI
Zeitfenster: day 29
day 29
BMI
Zeitfenster: day 31
day 31
Waist circumference
Zeitfenster: day 29
day 29
Waist circumference
Zeitfenster: day 31
day 31
Hip circumference
Zeitfenster: day 29
day 29
Hip circumference
Zeitfenster: day 31
day 31
Percentage body fat
Zeitfenster: Baseline
Baseline
Percentage body fat
Zeitfenster: day 29
day 29
Percentage body fat
Zeitfenster: day 31
day 31
Percentage lean body mass
Zeitfenster: Baseline
Baseline
Percentage lean body mass
Zeitfenster: day 29
day 29
Percentage lean body mass
Zeitfenster: day 31
day 31
Heart rate variability (resting)
Zeitfenster: Baseline
supine
Baseline
Heart rate variability (resting)
Zeitfenster: day 29
supine
day 29
Heart rate variability (resting)
Zeitfenster: day 31
supine
day 31
Heart rate variability (ambulatory)
Zeitfenster: 24 h recording at baseline
24 h recording at baseline
Heart rate variability (ambulatory)
Zeitfenster: 24 h recording on day 29
24 h recording on day 29
Heart rate variability (ambulatory)
Zeitfenster: 24 h recording on day 31
24 h recording on day 31
Heart rate variability (sleep-time)
Zeitfenster: Baseline
Baseline
Heart rate variability (sleep-time)
Zeitfenster: day 29
day 29
Heart rate variability (sleep-time)
Zeitfenster: day 31
day 31
Heart rate variability (during mental stress)
Zeitfenster: Baseline
Baseline
Heart rate variability (during mental stress)
Zeitfenster: day 29
day 29
Heart rate variability (during mental stress)
Zeitfenster: day 31
day 31
Ambulatory blood pressure 24 h
Zeitfenster: 24 h analysis at baseline
24 h analysis at baseline
Ambulatory blood pressure daytime
Zeitfenster: Daytime analysis at baseline
Daytime analysis at baseline
Ambulatory blood pressure night-time
Zeitfenster: Night-time analysis at baseline
Night-time analysis at baseline
Ambulatory blood pressure 24 h
Zeitfenster: 24 h analysis on day 29
24 h analysis on day 29
Ambulatory blood pressure daytime
Zeitfenster: daytime analysis on day 29
daytime analysis on day 29
Ambulatory blood pressure night-time
Zeitfenster: night-time analysis on day 29
night-time analysis on day 29
Ambulatory blood pressure 24 h
Zeitfenster: 24 h analysis on day 31
24 h
24 h analysis on day 31
Ambulatory blood pressure daytime
Zeitfenster: Daytime analysis on day 31
day time
Daytime analysis on day 31
Ambulatory blood pressure night-time
Zeitfenster: Night-time analysis on day 31
night-time
Night-time analysis on day 31
Digital volume pulse - stiffness index (SI)
Zeitfenster: Baseline
Stiffness index
Baseline
Digital volume pulse - SI
Zeitfenster: day 29
Stiffness index
day 29
Digital volume pulse - SI
Zeitfenster: day 31
Stiffness index
day 31
Digital volume pulse - reflection index (RI)
Zeitfenster: Baseline
reflection index
Baseline
Digital volume pulse - RI
Zeitfenster: day 29
reflection index
day 29
Digital volume pulse - RI
Zeitfenster: day 31
reflection index
day 31
Mnemonic Similarity Test
Zeitfenster: Baseline
Baseline
Mnemonic Similarity Test
Zeitfenster: day 29
day 29
Mnemonic Similarity Test
Zeitfenster: day 31
day 31
Power of food scale
Zeitfenster: Baseline
questionnaire
Baseline
Power of food scale
Zeitfenster: day 29
questionnaire
day 29
Power of food scale
Zeitfenster: day 31
questionnaire
day 31
COPE (not an acronym)
Zeitfenster: Baseline
questionnaire
Baseline
COPE
Zeitfenster: day 29
questionnaire
day 29
COPE
Zeitfenster: day 31
questionnaire
day 31

Andere Ergebnismessungen

Ergebnis Maßnahme
Zeitfenster
Adverse events
Zeitfenster: Baseline until endpoint: day 31 (+/-1 day)
Baseline until endpoint: day 31 (+/-1 day)

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Allgemeine Veröffentlichungen

Nützliche Links

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn

1. Februar 2016

Primärer Abschluss (Tatsächlich)

1. Juli 2016

Studienabschluss (Tatsächlich)

1. Juli 2016

Studienanmeldedaten

Zuerst eingereicht

22. Januar 2016

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

8. Februar 2016

Zuerst gepostet (Schätzen)

11. Februar 2016

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

17. September 2019

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

13. September 2019

Zuletzt verifiziert

1. Juli 2016

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

UNENTSCHIEDEN

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Klinische Studien zur Fettleibigkeit, Bauch

Klinische Studien zur Intermittent Energy Restriction

Abonnieren